Bullish
Argenx (NL0010832176) has received FDA approval to expand the label for Vyvgart Hytrulo to include adults with chronic inflammatory demyelinating poly...
Neutral
Argenx SE is gaining investor attention following updates on the commercial rollout of its autoimmune therapy Vyvgart and its broader antibody pipelin...
Neutral
Argenx SE remains in focus following its latest quarterly results, with particular attention on the growth of its lead therapy, Vyvgart, for generaliz...